For more updates follow Grant Thornton Bharat on WhatsApp
Assisting organisations in creating a difference in the lives of patients
India's pharmaceutical, biotechnology, and life sciences sector is one of the fastest-growing industries globally, fueled by an expanding domestic market.
Despite facing challenges such as regulatory hurdles, a shortage of skilled workers, high research and development costs, and intellectual property issues, the sector is poised for growth. Government support, strategic policy interventions, and the encouragement of foreign direct investment (FDI) are expected to stimulate further development in this dynamic industry.
Our private healthcare advisory teams operate on a global level and offer insights and practical guidance in the UK and internationally.
We have years of practical industry experience, which guarantees our understanding of the distinctive aspects that characterise your market.
Our technical expertise spans across the entire sector, from primary and secondary care providers to medical device companies, retail healthcare providers, and healthcare distributors.
As AI continues to transform other sectors, the life sciences industry has only recently begun to realize its full potential.
India’s pharma and healthcare sector remained active in Q3 2026 as organisations advanced consolidation, regional expansion and capability-building agendas.
India has, for a long time, played a central role in the global pharmaceutical supply chain due to its large scale, its scientific talent, and its ability to manufacture at a low cost.
In Q2 2026, pharma and healthcare deal activity reflected a selective investment environment. Strategic acquisitions, portfolio strengthening and capability-led expansion remained key themes across the sector.
